Skip to main content
. 2020 Jun 25;35(25):e236. doi: 10.3346/jkms.2020.35.e236

Table 5. Treatment and outcome features of pediatric inpatients with coronavirus disease 2019.

Variables Total (n = 44) ≤ 5 yr (n = 20) > 5 yr (n = 24) P value
Treatments
Antibiotics 42 (95) 18 (90) 24 (100) 0.204a
Ceftriaxone/cefotaxime 8 (18) 6 (30) 2 (8) 0.078a
Azitromycine 42 (95) 18 (90) 24 (100) 0.205a
Antiviral treatment 0 (0) - - -
Corticosteroids 2 (5) 2 (10) 0 (0) -
Intravenous immunoglobin 0 (0) - - -
Nasal cannula oxygen therapy 1 (2) 1 (5) 0 (0) -
Inhaled corticosteroids 1 (2) 1 (5) 0 (0) -
Diagnosis
Asymptomatic infection 7 (16) 5 (25) 2 (8) 0.154a
Upper respiratory infection 4 (9) 3 (15) 1 (4) 0.085a
Pneumonia 33 (75) 12 (60) 21 (88) 0.068a
Outcomes
Intensive care 2 (5) 2 (10) 0 (0) -
Time taken to become SARS-CoV-2 RT-PCR-negative, days 5 (3–10) 6 (3–10) 4 (3–9) 0.037b
No. of samples taken to get negative SARS-CoV-2 RT-PCR results 3 (2–4) 3 (2–4) 2 (2–4) 0.061b
Total duration of fever, days 1 (0–3) 1 (0–3) 1 (0–3) 0.404b
Total duration of cough, days 1 (0–2) 1 (0–2) 1 (0–2) 0.358b
Total duration of dyspnea or tachypnea, days 1 (0–2) NA 0.5 (0–2) -
Total duration of sore throat, days 1 (0–2) NA 1 (0–2) -
Total duration of runny nose, days 1 (0–1) NA 1 (0–1) -
Total duration of fatigue or myalgia, days 1 (0–1) NA 1 (0–1) -
Total duration of headache, days 1 (0–2) NA 0.5 (0–2) -
Total duration of vomiting or diarrhea, days 1 (0–2) 1 (0–2) 1 (0–2) 0.359b
Total duration of hospitalization, days 5 (4–10) 6 (4–10) 5 (4–7) 0.018b
Total duration in intensive care unit, days 8.5 (8–9) 8.5 (8–9) NA -

Values are presented as median (interquartile range) or number (%).

SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2, RT-PCR = reverse-transcription polymerase chain reaction, NA = not applicable.

aχ2 test; bMann Whitney-U test.